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DLX1 acts as a crucial target of FOXM1 to promote ovarian
cancer aggressiveness by enhancing TGF-β/SMAD4 signaling
DW Chan1, WWY Hui1, JJ Wang2,3, MMH Yung1, LMN Hui1, Y Qin3, RR Liang1, THY Leung1, D Xu4,5, KKL Chan1, K-M Yao2,
BK Tsang6,7,8 and HYS Ngan1
Recent evidence from a comprehensive genome analysis and functional studies have revealed that FOXM1 is a crucial metastatic
regulator that drives cancer progression. However, the regulatory mechanism by which FOXM1 exerts its metastatic functions in
cancer cells remains obscure. Here, we report that DLX1 acts as a FOXM1 downstream target, exerting pro-metastatic function in
ovarian cancers. Both FOXM1 isoforms (FOXM1B or FOXM1C) could transcriptionally upregulate DLX1 through two conserved
binding sites, located at +61 to +69bp downstream (TFBS1) and − 675 to − 667bp upstream (TFBS2) of the DLX1 promoter,
respectively. This regulation was further accentuated by the signiﬁcant correlation between the nuclear expression of FOXM1 and
DLX1 in high-grade serous ovarian cancers. Functionally, the ectopic expression of DLX1 promoted ovarian cancer cell growth, cell
migration/invasion and intraperitoneal dissemination of ovarian cancer in mice, whereas small interfering RNA-mediated DLX1
knockdown in FOXM1-overexpressing ovarian cancer cells abrogated these oncogenic capacities. In contrast, depletion of FOXM1
by shRNAi only partially attenuated tumor growth and exerted almost no effect on cell migration/invasion and the intraperitoneal
dissemination of DLX1-overexpressing ovarian cancer cells. Furthermore, the mechanistic studies showed that DLX1 positively
modulates transforming growth factor-β (TGF-β) signaling by upregulating PAI-1 and JUNB through direct interaction with SMAD4
in the nucleus upon TGF-β1 induction. Taken together, these data strongly suggest that DLX1 has a pivotal role in FOXM1 signaling
to promote cancer aggressiveness through intensifying TGF-β/SMAD4 signaling in high-grade serous ovarian cancer cells.
Oncogene advance online publication, 5 September 2016; doi:10.1038/onc.2016.307
INTRODUCTION
Forkhead box M1 (FOXM1) is a member of the Forkhead box
family, with a conserved winged-helix DNA-binding domain.1 It is
critically involved in embryogenesis and organ development.2,3
Alternative splicing of FOXM1 generates three variants; FOXM1A
contains alternative exons Va and VIIa, FOXM1C contains Va, and
FOXM1B contains none of these exons. Both FOXM1B and
FOXM1C are transcriptionally active, whereas FOXM1A is tran-
scriptionally inactive, due to an insertion of exon VIIa in the
transactivation domain (TBD).4 Emerging evidence has documen-
ted that aberrant upregulation of FOXM1 is frequently observed in
various human cancers.5–8 According The Cancer Genome Atlas
(TCGA), activated FOXM1 is signiﬁcantly associated with the
majority of high-grade serous ovarian cancers, which is the most
common and deadly subtype of epithelial ovarian cancer.9 FOXM1
exhibits potent oncogenic properties in promoting cell prolifera-
tion in human cancer cells, and acts as a major activator of cancer
metastasis through enhancing the epithelial–mesenchymal transi-
tion, invasion, cell migration and angiogenesis.10–12 Indeed, we
have previously reported a stepwise increase in FOXM1 expression
from low- to high-grade ovarian cancer.13 We have also
demonstrated that FOXM1B has a higher capacity to enhance
cell migration and cell invasion, while FOXM1C is involved in not
only cell migration and invasion of ovarian cancer cells but also
cell proliferation.13 Given that FOXM1 acts as a crucial master
regulator of tumorigenesis and metastasis in human cancers, it is
of interest to understand the underlying molecular mechanism of
FOXM1 in the transcriptional regulation of the diverse signaling
pathways in each step of tumorigenesis. The identiﬁcation of
downstream targets of FOXM1 will provide reliable biomarkers
and better therapeutic targets for the tailored treatment of
ovarian cancers.
The DLX homeobox family is a group of transcription factors
that show sequence homology to the Drosophila distal-less genes
(Dll).14 DLX genes are essential in the development of appendages,
craniofacial structures, sensory organs, brains, bones and blood,
but their expression is variable in different developmental
stages.15 Aberrant expression of homeobox genes has been
found in a variety of human cancers. For examples, DLX4 is highly
correlated with high-grade and metastatic stages of ovarian
cancer.16 The oncogenic function of DLX4 is due to its capacity to
inhibit the expression of p15lnk4B and p21WAF1/Cip1 by blocking
Smad4 in the Transforming growth factor-β (TGF-β) signaling
pathway.17 Moreover, DLX5 upregulation promotes ovarian cancer
cell growth via the AKT signaling pathway.18 Moreover, the
expression of DLX2 and DLX5/6 is associated with the metastatic
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potential of a variety of human cancer cells.15,19 Within the
DLX family, little is known about the oncogenic role of DLX1.
However, recent reports have shown that DLX1 is important for
controlling the proliferation and migration of GABAergic cortical
interneuron.20,21 Importantly, DLX1 has been found to be
associated with the metastatic state in prostate cancer,22
indicating that DLX1 might have an oncogenic role in cancer
progression.
In this study, we have identiﬁed DLX1 as a novel target of
FOXM1 and showed that DLX1 is upregulated in high-grade
ovarian cancer. In vitro and in vivo tumorigenic assays revealed
that DLX1 could promote cell growth and migration/invasion, two
common metastatic properties in high-grade ovarian cancer, by
modulating the TGF-β1/SMAD4 signaling pathway. Taken
together, these data highlight the possibility that DLX1 could be
used as a biomarker and therapeutic target in combating ovarian
cancer in the future.
RESULTS
Prediction of the putative downstream targets of FOXM1
The position weight matrix (PWM) of FOXM1 (Figure 1a) was used
to scan all human promoters for putative FoxM1-binding sites
based on their predicted binding afﬁnity according to our FastPval
calculation.23 The search led to the identiﬁcation of three
categories of putative transcription factor binding sites (TFBSs)
(highly conserved, moderately conserved, and conserved, with
conservation P-value at 0.001, 0.005 and 0.05 respectively)
(Figure 1b). To avoid the false positive targets, we only selected
the predicted TFBSs with moderately conservation (P-valueo0.005)
between human and mouse for further screening (Supplementary
Table S1). To verify that these putative genes are transcriptionally
upregulated by FOXM1, a plasmid expressing the most common
FOXM1 isoform, FOXM1C, was transiently transfected into HEK293
cells, and the quantitative real-time PCR (qRT-PCR) results showed
that three out of the 18 putative targets (namely DLX1, PRDM16
and FOXP2) exhibited a progressive increase in mRNA expression
that was concomitant with Cyclin D1 expression in dose-
dependent manner, and the increased DLX1 mRNA was most
remarkable (Figure 1c). On the other hand, other 15 genes just
showed mild to moderate increases in their mRNA levels (data not
shown). On the other hand, after inhibiting FOXM1 expression
using Thiostrepton (FOXM1 inhibitor; 5 μM) (76.7% reduction) or an
shRNAi approach (87% reduction) on A2780cp cells, we found that
there were concomitant decreases in expression of DLX1 (50% to
65%), PRDM16 (15% to 18%) and FOXP2 (48–50%) compared with
the untreated or scrambled control A2780cp cells (Figure 1d).
In view of these ﬁndings, DLX1 was the most responsive
candidate that best correlated with FOXM1 expression in ovarian
cancer cells.
DLX1 is a downstream target of FOXM1 in ovarian cancer cells
Previous ﬁndings have suggested that two FOXM1 active isoforms,
FOXM1B and FOXM1C, have differential oncogenic capacities in
ovarian cancer cells.13,24 To conﬁrm which FOXM1 isoform has a
higher transcriptional ability to upregulate DLX1, both FOXM1B
and FOXM1C expression plasmids were individually transiently
transfected into A2780cp and OVCA433 cells. The qRT-PCR
analysis showed that FOXM1B and FOXM1C upregulated the
expression of DLX1 by 45-fold and 35-fold, respectively, in
A2780cp cells, and by 50-fold and 40-fold, respectively, in
OVCA433 cells (Figure 2a). Similarly, the western blot analysis
conﬁrmed that the transient transfection of FOXM1B or FOXM1C
induced a concomitant upregulation of DLX1 in both A2780cp and
Figure 1. Prediction of the putative downstream targets of FOXM1 by PWMSCAN. (a) PWM for FOXM1-binding motif sequence.
(b) A schematic diagram summarizing the computational predictions of the putative targets of FOXM1, which are divided into three groups
based on the positions of the FOXM1-binding sites. The genes are further classiﬁed into three subgroups according to degree of human–
mouse conservation of their putative binding sites. (c) Western blot and qRT-PCR analyses showed concentration-dependent increases in
DLX1, PRDM16 and FOXP2 expression following transient transfection of a FOXM1 expression plasmid. The expression of CyclinD1 was used as a
positive control for FOXM1 expression. Both β-actin and GAPDH were used as internal controls. (d) The qRT-PCR analysis showed that the
inhibition of FOXM1 by treatment with Thiostrepton inhibitor (5 μM, 24 h) or shRNAi-mediated FOXM1 knockdown was accompanied by a
remarkable reduction of the three putative targets, DLX1, PRDM16 and FOXP2, compared with their respective untreated or scrambled controls
of A2780cp (*Po0.01 and **Po0.05, Student’s t-test).
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OVCA433 cells (Figure 2b), and the induction of DLX1 by both
isoforms varied in the different ovarian cancer cells, indicating that
there was no signiﬁcant difference in the ability of both isoforms
to activate DLX1 transcription (Supplementary Figure S1). On the
other hand, silencing of endogenous FOXM1 with an shRNA
reduced the DLX1 mRNA expression by more than 50% in both the
A2780cp and OVCA433 cells (Po0.05; Figure 2c). The western
blots also showed a decrease in the levels of the DLX1 protein in
A2780cp and OVCA433 cells when FOXM1 was depleted by a
FOXM1 shRNA (Figure 2d). These ﬁndings suggest that DLX1 is the
downstream target of FOXM1 in ovarian cancer cells.
Transcriptional activation of DLX1 by FOXM1
As DLX1 is a downstream target of FOXM1, we hypothesized that
FOXM1 directly regulates DLX1 by transcriptional activation of the
DLX1 promoter. To test this notion, we constructed three DLX1
promoter luciferase reporters and used them in transient
transfections and reporter assays. According to the Transfac
database using the PWM as a comparison, two putative FOXM1-
binding sites in the DLX1 promoter located at +61 to +69bp and
− 675 to − 667bp upstream and downstream of the transcription
start site (TSS) were identiﬁed. The +61 to +69bp binding site 1
(TFBS1; ACTCCATTT, reverse strand AAATGGAGT) is the more
conserved binding site, while the − 675 to − 667bp binding
site 2 (TFBS2; ACTCCAGCT, reverse strand AGCTGGAGT) is less
conserved. Three luciferase reporter constructs were generated;
pGL3-DLX1 II includes both TFBS1 and TFBS2, whereas
pGL3-DLX1 I includes only TFBS1. pGL3-DLX1 N, which was
used as a negative control, does not contain any of the
predicted binding sites (Figure 3a). We found that both
pGL3-DLX1 I and pGL3-DLX1 II could be activated by either
FOXM1B or FOXM1C overexpression (Po0.05; Figure 3a).
Noticeably, pGL3-DLX1 II, which contains both the conserved
TFBS1 and the less conserved TFBS2, showed stronger activity
compared with pGL3-DLX1 I, which contains only the conserved
TFBS1 (Figure 3a). On the other hand, pGL3-DLX1 N, which
does not have any of the predicted binding sites, did not
show an increase in activity upon FOXM1B or FOXM1C
overexpression (Figure 3a). These data showed that without
TFBS2, the luciferase activity of the DLX1 promoter with TFBS1
was still induced by twofold when transfected with FOXM1B
(Po0.01) or by 1.5-fold when transfected with FOXM1C
(Po0.05).
A chromatin immunoprecipitation (ChIP) assay was performed
to demonstrate the direct binding of FOXM1 on the DLX1
promoter. Using the ﬂanking primers at TFBS1 and TFBS2, our
data clearly showed that FOXM1 could directly interact with TFBS1
or TFBS2 on the DLX1 promoter (Figure 3b).
Collectively, our ﬁndings strongly support that FOXM1 could
transcriptionally activate DLX1 by interacting with two predicted
binding sites, TFBS1 and TFBS2, in the DLX1 promoter.
Figure 2. Identiﬁcation of DLX1 as a downstream target of FOXM1. (a) The qRT-PCR analysis showed that DLX1 expression was upregulated by
40-fold and 35-fold in the A2780cp cells, and by 50-fold and 40-fold in OVCA433 cells (**Po0.01, Student’s t-test) after transient transfection
of FOXM1B or FOXM1C, respectively. (b) The western blot analysis showed that both FOXM1B and FOXM1C upregulate DLX1 expression in
OVCA433 and A2780cp cells. (c) The qRT-PCR analysis demonstrated a 20 and 40% reduction of DLX1 expression in the A2780cp (*P= 0.03,
Student t-test) and OVCA433 cells (*P= 0.02, Student’s t-test) following the depletion of endogenous FOXM1 by shRNA, respectively. (d) The
western blot analysis showed that FOXM1 knockdown reduces DLX1 expression in the A2780cp and OVCA433 cells. The 18S RNA was used as
an internal control for all qRT-PCR analyses.
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Elevated DLX1 expression correlates with high-grade ovarian
cancers
As DLX1 is a downstream target of FOXM1 and is capable of
promoting FOXM1-mediated ovarian cancer cell growth and
migration, we sought to evaluate the expression status of DLX1
and FOXM1 in human ovarian and cervical cancers. Out of the
seven tested cancer cell lines, A2780cp, A2780s, C13*, SKOV3,
OVCA429 and OVCA433 showed an increased DLX1 expression
concomitant with FOXM1 expression compared with the immor-
talized ovarian surface epithelium cell line HOSE 96-6 (Figure 3c).
We next determined the expression levels of the DLX1 and
FOXM1 mRNAs in normal ovarian clinical samples (n= 37) and
ovarian cancer samples (n= 43) by qRT-PCR. FOXM1 was
remarkably elevated in the ovarian cancer samples (20-fold)
compared with the normal ovaries (P= 0.032), while the expres-
sion of DLX1 was approximately 14-fold higher in ovarian cancer
samples (P= 0.048; Figure 3d). As expected, FOXM1 and DLX1
expression showed a strong positive correlation in the ovarian
cancer samples, as tested by Spearman's non-parametric correla-
tion test (coefﬁcient value = 0.813, Po0.01; Supplementary
Figure S2).
A commercially available ovarian cancer tissue array (OVC1021)
was subjected to immunohistochemical analysis to further
examine the expression of DLX1 and its clinical signiﬁcance.
As expected, both FOXM1 and DLX1 were frequently over-
expressed in ovarian cancer samples. Using twofold and eightfold
as the cutoff points for the expression of FOXM1 and DLX1,
respectively, we found that that DLX1 overexpression was
signiﬁcantly associated with high-grade serous ovarian cancers
(Po0.001) and FOXM1 overexpression (P= 0.002) (Table 1).
Intriguingly, the expression of both FOXM1 and DLX1 showed a
progressive increase from low- to high-grade serous ovarian
Figure 3. FOXM1 and DLX1 are concomitantly expressed in high-grade serous ovarian cancers. (a) TFBS1 and TFBS2 are the two conserved
FOXM1-binding sites on the DLX1 promoter. (left) A schematic diagram illustrating the DLX1 promoter luciferase reporter constructs: pGL3-
DLX1 I with only one putative FOXM1-binding site, pGL3-DLX1 II with both putative FOXM1-binding sites, and pGL3-DLX1 II with none of the
predicted binding sites. (right) The luciferase promoter assay demonstrated the ability of FOXM1 to transcriptionally activate DLX1 by binding
to the two FOXM1-binding sites. Both FOMX1B and FOXM1C could increase the luciferase activity of the pGL3-DLX1 I and pGL3-DLX1 II
constructs in a concentration-dependent manner (*Po0.05 and **Po0.01, Student’s t-test). pGL3-DLX1 N, which does not have any of the
predicted binding sites, shows no observable change in luciferase reporter activity. (b) The ChIP assay demonstrated that PCR fragments from
the TFBS1 and TFBS2 sites were pulled down with the FOXM1 antibody (C-20) in a concentration-dependent manner. TFBSN was used as a
negative control. (c) Western blot showing the FOXM1 and DLX1 levels in panels of ovarian cancer cell lines and a HOSE cell line. β-actin was
used as a control. (d) The qRT-PCR analysis illustrated that FOXM1 (*P= 0.032, Student’s t-test) and DLX1 (*P= 0.048, Student’s t-test) expression
were upregulated in ovarian cancer samples (n= 43 cases) compared with the normal ovaries (n= 37 cases). The 18S RNA was used as the
internal control. (e) Representative photos showing the immunohistochemical images of FOXM1 and DLX1 staining on the ovarian cancer
tissue array. Both FOXM1 and DLX1 expression were progressively increased from borderline cystadenocarcinoma to Grade 3 serous
cystadenocarcinoma. (Magniﬁcation x100).
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cancer, based on the semi-quantitative scoring system using the
staining intensity and area of the positive immunohistochemical
analysis staining (Figure 3e). Together, these data further support
the notion that DLX1 is a downstream target of FOXM1 and that
their overexpression is closely associated with the development of
high-grade ovarian cancer that features increased cellular
proliferation and migration.
The role of DLX1 in ovarian cancer cell growth and cell migration
FOXM1 is a crucial metastatic regulator that governs a wide range
of cellular behaviors, including uncontrolled cell proliferation,
increased cell survival, increased DNA repair and an enhanced
epithelial–mesenchymal transition in numerous human cancers.12
If DLX1 is indeed a physiological downstream target of FOXM1 in
mediating cancer metastasis, we would expect that, like FOXM1,
DLX1 would be critically required for cancer metastasis. Emerging
evidence has shown that DLX1 is important for GABAergic neuron
development,25 while Dlx1 knockout mice showed a substantial
loss of GABAergic neurons.26 DLX1 may be similarly required for
regulating ovarian cancer cell proliferation. To examine the
oncogenic functions of DLX1 in ovarian cancer cells, transient
transfection of DLX1 was initially performed in ovarian cancer
cells. Results showed that enforced expression of DLX1 signiﬁ-
cantly enhanced cell proliferation (Po0.001) and cell migration
rates of OVCA433 (P= 0.04) and SKOV3 (Po0.0001) cells
(Supplementary Figure S3). To further investigate the functional
role of DLX1 in ovarian cancer cells, clones that stably express
DLX1 were generated in the SKOV3 (SK-C1 and SK-C2) and
OVCA433 (OV-C1) cells (Figure 4a). As expected, we found
that DLX1 overexpression exhibited a 1.5–3-fold increase in the
cell growth rate of the SKOV3 (SK-C1 and SK-C2; Po0.05)
and OVCA433 (OV-C1) cells using the XTT cell viability assay
(P= 0.03; Figure 4a). In contrast, depletion of DLX1 in two
FOXM1-overexpressing ovarian cancer cell lines (SKOV3 and
OVCA433) by siRNA knockdown decreased the growth rate. Two
out of the three siRNAs (si2 and si3) showed a signiﬁcant
reduction of 60–80% and 70–90% of endogenous DLX1 in the
SKOV3 and OVCA433 cells, respectively (Figure 4b). The XTT cell
viability assay showed that the depletion of DLX1 resulted in an
approximately 1.5-fold reduction of the cell growth rate in the
SKOV3 and OVCA433 cells (Po0.05; Figure 4b). Moreover, a focus
formation assay conﬁrmed that DLX1 overexpression in the SKOV3
(SK-C1 and SK-C2) and OVCA433 (OV-C1) cells increased both the
colony number and colony size compared with the vector controls
(Supplementary Figure S4).
FOXM1 upregulation promotes cell proliferation, cell migration
and invasion.11,13 It is worth noting that DLX1 is able to modulate
the migration of GABAergic interneurons from the proliferative
zone to the differentiated zone of the cortex in previous
studies,27,28 but its role in cancer cell migration remains unclear.
Therefore, it is worth testing whether DLX1 has a role in FOXM1-
mediated ovarian cancer cell migration. Using a wound-
healing assay, we showed that DLX1 overexpression in the SKOV3
(SK-C1 and SK-C2; Po0.05) and OVCA433 (OV-C1; P= 0.002) cells
increased the wound closure rate by twofold compared with the
vector control (Supplementary Figure S5A). Conversely, DLX1
knockdown signiﬁcantly reduced the cell migration rate by 50%
(Po0.05) and 60% (Po0.01) in SKOV3 and OVCA433 cells,
respectively (Supplementary Figure S5B). In addition, using the
Transwell cell migration assay, we further conﬁrmed that DLX1
overexpression could increase the cell migration rate by ~ 1.5-fold
in the SKOV3 cells (SK-C2; P= 0.03) and by 2.5-fold in the OVCA433
cells (OV-C1; P= 0.001; Figure 4c). In contrast, DLX1 depletion by
the siRNA markedly blocked the cell migration rate by 60%
(P= 0.03) and 13% (P= 0.04) in the SKOV3 and OVCA433 cells,
respectively (Figure 4d).
Taken together, these ﬁndings suggest that DLX1 is required for
ovarian cancer cell proliferation and migration, and it may be
an important effector of FOXM1-stimulated ovarian cancer
metastasis.
DLX1 has a key role in FOXM1 signaling to promote cancer
metastasis
Previous studies have reported that TGF-β1 enhances the ovarian
cancer cell epithelial–mesenchymal transition, migration/invasion
and metastasis;29–31 however, it is not clear whether DLX1
synergistically increases the ability of TGF-β1 in cancer cell
migration/invasion. Using the Transwell cell invasion assay,
TGF-β1 treatment (5 ng/ml) increased the invasive capacity of
both the vector control cells and DLX1 stably overexpressing clone
(SK-C2) by ~ 45%, while the SK-C2 cells exhibited higher invasive
capacity (Figure 5a). Moreover, knockdown of FOXM1 by shRNA
strongly inhibited SKOV3 cell migration in the absence and
presence of TGF-β1 (5 ng/ml) (Figure 5a), suggesting FOXM1 is a
critically involved in ovarian cancer cell invasion. Of note, DLX1
overexpression in the FOXM1 knockdown SKOV3 cells (SK-C2)
could still maintain higher cellular invasion rate with or without
TGF-β1 (5 ng/ml) treatment (Figure 5a). This ﬁnding indicates that
DLX1 is the dominant regulator of FOXM1-mediated ovarian
cancer cell invasion.
Given that DLX1 enhances cell proliferation and cell migration/
invasion in vitro, we next assessed the tumorigenic capacity of
DLX1 in tumor growth and cancer cell dissemination using an
orthotopic mouse model of ovarian cancer. Luc-labeled SKOV3
cells with or without stable DLX1 expression were injected
intraperitoneally (i.p.) into 5-week-old female nude mice. The
tumor burden was monitored by a Xenogen living animal system.
As expected, the DLX-1-expressing SKOV3 cells (SK-C2) developed
tumors 2.5-fold faster than the vector control (SK-vector) from 0 to
28 days (P= 0.01, Fisher’s exact test; Figure 5b). A post-mortem
examination revealed that the DLX1-expressing SKOV3 (SK-C2)
cells had higher capacity of peritoneal dissemination than the
vector control (SK-vector) SKOV3 cells. All nude mice (n= 5) that
were i.p. injected with the SK-C2 cells showed ~ 48% more
disseminated tumor nodules throughout the peritoneal cavity and
a ~ 43% higher tumor burden than SK-vector cells (Figure 4c).
Table 1. Immunohistochemical analysis of FOXM1 and DLX1 on an
ovarian cancer tissue array (OVC1021, Pantomics, Inc.)
Characteristics Total DLX1 expression (fold change) P-value
⩽ Eightfold 4Eightfold
All cases 97 47 (48.5%) 50 (51.5%)
Stage
Early (1) 48 25 (52.1%) 23 (47.9%)
Late (2 and 3) 49 22 (44.9%) 27 (55.1%) 0.545
Grade
Low (1 and 2) 50 36 (72.0%) 14 (28.0%)
High (3) 46 10 (21.7%) 36 (78.3%) o0.001*
Metastasis
No 73 36 (49.3%) 37 (50.7%)
Yes 24 11 (45.8%) 13 (54.2%) 0.817
FOXM1 (2xfold)
Underexpression 58 36 (62.1%) 22 (37.9%) 0.002*
Overexpression 39 11 (28.2%) 28 (71.8%)
Higher expression of DLX1 was found in higher tumor grading (*Po0.001,
Fisher's exact test). No signiﬁcant difference was found in tumor stages and
metastatic status. DLX1 was positively correlated with FOXM1 expression in
immunohistochemical analysis (*P= 0.002, Fisher's exact test).
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Even after depletion of FOXM1, the DLX1-expressing cells (SK-C2)
still exhibited ~ 38% more disseminated tumor nodules and a
~ 32% higher tumor burden than the vector control cells
(Figure 5c). Histologically, the disseminated tumor showed that
the blood vessels had inﬁltrated from disseminated site (liver) to
the tumor nodule, whereas there were no invasive cancer cells
present in liver tissue (Figure 5d). These data conﬁrm that DLX1
has a critical role in enhancing the peritoneal dissemination of
ovarian cancer cells in vivo.
DLX1 modulates TGF-β1 signaling in ovarian cancer cells by
interacting with SMAD4
The above data indicate that DLX1 requires TGF-β1 to promote
ovarian cancer cell proliferation and cell migration/invasion.
Indeed, a recent study reported that DLX1 interacts with SMAD4
and blocks the action of TGF-β1 family members (for example,
activin A, TGF-β1 and BMP-4),32 suggesting that DLX1 governs
these ovarian cancer cell phenotypes by modulating TGF-β/
SMAD4 signaling. To conﬁrm DLX1 whether actually interacts with
SMAD4 in ovarian cancer cells, the SKOV3 cells were transfected
with the Myc-DDK-tagged HuDLX1 plasmid and treated with/
without of TGF-β1 (5 ng/ml) for 5 h. Intriguingly, only the TGF-β1-
treated SKOV3 cells exhibited an interaction between DDK-tagged
DLX1 and endogenous SMAD4 (Figure 6a). This observation was
further conﬁrmed by immunoﬂuorescent analysis showing that
DDK/DLX1 was predominantly localized in the nucleus, and co-
localized with GFP/SMAD4 when the SKOV3 and OVCA433 cells
were treated with TGF-β1 (5 ng/ml, 3 h; Figure 6b). Our study also
showed that DLX1 interacts with the majority of SMAD4 in the
nucleus of ovarian cancer cells upon TGF-β1 stimulation
Figure 4. DLX1 is able to enhance cell proliferation and cell migration. (a) SKOV3 and OVCA433 (OV-C1) cells stably expressing DLX1. Vector
represents the vector control. The XTT cell proliferation assay showed that cell proliferation was signiﬁcantly increased in the SKOV3 cells by
1.5-fold (SK-C1 and SK-C2) (*Po0.05, Student’s t-test) and in the OVCA433 cells (OV-C1) by twofold (**P= 0.03, Student’s t-test) following DLX1
overexpression. (b) Successful DLX1 knockdown in SKOV3 and OVCA433 cells with two siRNA oligonucleotides (si2 and si3). The XTT cell
proliferation assay demonstrated that the cell growth rate of the DLX1 knockdown SKOV3 and OVCA433 cells was decreased by ~ 1.5-fold and
by twofold, respectively, compared with their scrambled controls (*Po0.05, Student’s t-test). (c) The cell migration rate of the SKOV3 (SK-C2)
(*P= 0.03, Student t-test) and OVCA433 (OV-C1) cells was increased by 1.5-fold and 2.5-fold, respectively (**P= 0.001, Student’s t-test),
following DLX1 overexpression. (d) The migration of the SKOV3 and OVCA433 cells was reduced by twofold (**P= 0.03, Student’s t-test) and
onefold (**P= 0.04, Student’s t-test), respectively, following DLX1 knockdown.
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(Figure 6b), and that DLX1 signiﬁcantly inhibited TGF-β1
(10 ng/ml)-induced p21WAF1/Cip1 transcriptional activity in a
concentration-dependent manner (Figure 6c). Both the qRT-PCR
and western blot analyses conﬁrmed that DLX1 reduced the
mRNA and protein levels of p21WAF1/Cip1 in ovarian cancer cells
(Figures 6d and e). To investigate whether the expression patterns
of other cell cycle regulators affected by DLX1/SMAD4 upon TGF-
β1 treatment, we employed western blot analysis to evaluate the
common cell cycle regulators, for example, p15Ink4B, p18Ink4c
and p27Kip1 in OVCA433 cells with transiently transfected with
DDK/DLX1 and GFP/SMAD4. Results showed that p21 WAP1/Cip1
was signiﬁcantly suppressed, while p15Ink4B was moderately
reduced by co-expression of DLX1 and SMAD4 (Supplementary
Figure S6A). But another two cell cycle regulators, p18Ink4c and
p27Kip1, were slightly or no change when compared with their
controls (Supplementary Figure S6A). These ﬁndings suggest that
DLX1 promotes ovarian cancer cell growth by mainly suppression
of TGF-β1-induced p21WAF1/Cip1 and partially by inhibition of
p15Ink4B. To examine whether the interaction of DLX1 interferes
the recruitment of SMAD4 to the promoter of p21WAF1/Cip1,
we used SMAD4 motif from Jaspar database to search the SMAD-
binding elements (SEBs) on the p21WAF1/Cip1 promoter
(Supplementary Figure S6B). Taking the promoter region (±3k to
TSS) of p21WAF1/Cip1: chr6:336641237-336647237, we found that
two SEBs; SEB1 (hg19_ct_SBE_7386_SBE1: AGGTCTGGCCCCT,
− 1759 ~− 1747 to TSS) and SEB2 (hg19_ct_SBE_7386_SBE2:
CACTCTGTCACCC, located at − 992 ~− 980 to TSS), showing higher
potential of SMAD4 binding and were supported by a recent
study.33 ChIP results showed that SMAD4 occupancy on the above
two SBEs of the p21WAF1/Cip1 promoter were apparently
attenuated by overexpression of DLX1 in ovarian cancer cells
(Supplementary Figure S6B), suggesting that DLX1 could retard
the recruitment of SMAD4 to the p21WAF1/Cip1 promoter.
On the other hand, the expression of plasminogen activator
inhibitor 1 (PAI-1) and JUNB, two TGF-β responsive genes involved
in cancer cell migration and invasion,34 was signiﬁcantly
upregulated in the DLX1-overexpressing SKOV3 cells (SK-C2)
compared with the vector control (Figure 7a). Intriguingly,
the upregulation of both PAI-1 and JUNB were co-existed
with the suppression of p21WAF1/Cip1 and p15Ink4B when
Figure 5. DLX1 dominantly regulates the tumor burden and cancer cell metastasis. (a) The Transwell cell invasion assay demonstrated a higher
invasion rate of the SKOV3 cells upon treatment with TGF-β1 (5 ng/ml). The invasion rate was further enhanced by ~ twofold in the DLX1-
overexpressing SKOV3 cells (SK-C2) in the presence or absence of TGF-β1 (5 ng/ml). Stable depletion of FOXM1 by shRNA reduced the
invasiveness of the SKOV3 cells (SK-vector) by ~ twofold, but reduced the invasion rate of the DLX1-overexpressing cells (SK-C2) to a lesser
extent (*Po0.05, Student’s t-test). (b) SKOV3-luc cells with or without DLX1 expression were intraperitoneally injected into BALB/c nu/nu
female mice. The DLX1-expressing SKOV3 (SK-C2) cells exhibited an ~ threefold increase in tumor growth compared with the vector control
(SK-vector) (*Po0.01, Student’s t-test). The mice were imaged at different time points (0, 10, 18 and 28 days) using a Xenogen IVIS 100 system
and Living Imaging, version 2.50.1. (c) The mice were killed on day 28; the gross images show the extensive dissemination of metastatic
nodules (green arrows) of the SK-vector, SK-C2 and SK-C2 with stable knockdown of FOXM1 clones. The quantiﬁcation of the intraperitoneal
tumor burden and the number of intraperitoneal nodules are presented in bar charts (*Po0.05, Student’s t-test). (d) Hemotoxylin and eosin
analysis showed a tumor nodule colonized on the liver. The boundary of tumor nodule showed an inﬁltrative growth front was toward the
liver with blood vessels penetrated from the liver to the tumor tissue.
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co-expression of DLX1 and SMAD4 simultaneously in OVCA433
cells (Supplementary Figure S6A). Previous studies have shown
that the expression of urokinase-type plasminogen activator (uPA)
and PAI-1 are regulated by TGF-β/SMAD4 signaling in metastatic
cancer cells.34,35 We thus attempted to examine whether DLX1
enhances the TGF-β/SMAD4-mediated transcriptional activity of
PAI-1, a PAI-1 promoter luciferase (p3TP) assay was performed.
The results showed that the PAI-1 promoter activity was
signiﬁcantly upregulated by DLX1 and TGF-β1 treatment in a
concentration-dependent manner (Figure 7b). However, depletion
of SMAD4 by shRNA approach impaired DLX1 in upregulation of
PAI-1 in SKOV3 cells (Figure 7e). These results indicate that PAI-1 is
a direct target and can be transcriptionally activated by DLX1
through interaction of SMAD4.
FOXM1 is known to be a master transcription factor modulating
the downstream transcriptional network.36 As DLX1 is a down-
stream target of FOXM1, it is of interest to examine the role of
DLX1 in regulating FOXM1-induced oncogenic genes. We thus
applied shRNA approach to knockdown DLX1 in OVCA433 and
SKOV3 cells. The results showed that depletion of DLX1
signiﬁcantly reduced the expression levels of PAI-1 and JUNB in
ovarian cancer cells (Figure 7c). On the other hand, it is generally
known that FOXM1 is frequently overexpressed in cancer cells,
including ovarian cancer cells.13 To determine whether DLX1 is the
critical downstream effector of FOXM1, we used FOXM1 knock-
down in SKOV3 cells that stably express DLX1 (SK-C2). The results
showed that FOXM1 could not alter the expression of PAI-1 and
JUNB in these cells (Figure 7d), supporting our notion that DLX1 is
a dominant downstream effector of FOXM1 in regulating the
oncogenes associated with cell migration or invasion. Moreover,
knockdown of SMAD4 (shSMAD4) in DLX1 stably overexpressing
SKOV3 (SK-C2) and subsequently treated them with TGF-β1
(5 ng/ml), the expression of PAI-1 and JUNB were signiﬁcantly
attenuated compared with the scrambled control (shctrl)
(Figure 7e), indicating that SMAD4 is required for DLX1-
mediated regulation of PAI-1 and JUNB expression. Collectively,
these ﬁndings suggest that DLX1 is a major downstream regulator
controlling the expression of the TGF-β responsive genes
Figure 6. DLX1 activates TGF-β1/SMAD4 signaling through a direct interaction with SMAD4 in the nuclei of ovarian cancer cells. (a) Reciprocal
co-immunoprecipitation (co-IP) demonstrated that DLX1 interacts with SMAD4. (upper) Co-transfection of DDK/MYC/DLX1 and MYC/SMAD4
in HEK293T cells and co-IP using anti-Flag (DDK) showed that DDK/MYC/DLX1 could pull down MYC/SMAD4 conﬁrmed by immunoblotting
using anti-MYC. Conversely, transfection of MYC/SMAD4 in HEK293T cells showed that co-IP using anti-MYC could pull down endogenous
DLX1 conﬁrmed by immunoblotting using anti-DLX1. (lower) Co-IP assay using anti-Flag (DDK) conﬁrmed that TGF-β1 (5 ng/ml, 5 h) induction
could enhance DDK/MYC/DLX1 to pull down more MYC/SMAD4 in SKOV3 and OVCA433 cells, indicating that TGF-β1 induces more MYC/
SMAD4 translocating into the nucleus and increases DLX1-SMAD4 interaction. (b) Immunoﬂuorescent analysis demonstrating DLX1-SMAD4
co-localization in the nuclei of the SKOV3 and OVCA433 ovarian cancer cells after TGF-β1 (5 ng/ml, 3 h and 5 h for SKOV3 and OVCA433,
respectively) stimulation. (c) DLX1 inhibits p21WAF1/CIP1 promoter activity upon TGF-β1 treatment. Various amounts of the Myc-DDK-tagged
HuDLX1 vector were co-transfected with the pWWP-luciferase reporter construct and empty vector pCMV2 into HEK293 cells. TGF-β1 (10 ng/
ml) was added 24 h after transfection and incubated for another 5 h before the luciferase activity was measured. The relative p21WAF1/CIP1
luciferase reporter activity of DLX1 was calculated by comparing the test samples with the empty vector control (**Po0.001, Student’s t-test).
(d) The qRT-PCR (**Po0.001, Student’s t-test) and (e) Western blot analyses showed a signiﬁcant reduction in the expression of p21WAF1/CIP1
in the SKOV3 cells that stably express DLX1 (C1 and C2) upon TGF-β1 treatment (10 and/or 20 ng/ml, 4 h).
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associated with cell growth and migration/invasion through
binding to nuclear SMAD4.
DISCUSSION
Emerging evidence has demonstrated that FOXM1 is an onco-
genic transcription factor and a master regulator of tumor
progression and metastasis.5,12,37 However, the regulatory net-
work of FOXM1, particularly the proteins that promote the
metastatic potential of cancer cells, is still not fully understood.
In this study, we identiﬁed DLX1 as the downstream target of
FOXM1, and its expression was temporally associated with FOXM1.
Functionally, DLX1 exhibited similar oncogenic functions in
promoting cell proliferation and cell migration by activating
TGF-β/SMAD4 signaling. Importantly, DLX1 overexpression was
correlated with high-grade ovarian cancer. To the best of our
knowledge, this is the ﬁrst demonstration of the role of a direct
downstream target of FOXM1 in governing these oncogenic
capacities in high-grade ovarian cancer.
A recent comprehensive genomic analysis indicated that the
FOXM1 and NOTCH signaling pathways are frequently deregu-
lated and signiﬁcantly associated with ovarian cancer oncogenesis
(The Cancer Genome Atlas Research Network). Indeed, we and
others have reported that aberrant activation of FOXM1 signaling
is frequently involved in cancer progression by regulating the cell
cycle, cell proliferation, the epithelial–mesenchymal-like transition,
cell migration, invasion, angiogenesis and so on.12,13,38–40
However, the downstream targets or signaling pathways regu-
lated by FOXM1 during ovarian cancer progression are still largely
unknown. Therefore, investigations of this gray area may help to
delineate the molecular mechanism underlying the role of FOXM1
in ovarian cancer oncogenesis. Our study also sheds light on
biomarkers and therapeutic targets for the early diagnosis and
treatment of this disease.
In this study, we identiﬁed DLX1 as a downstream target of
FOXM1, based on bioinformatics predictions and the results from
a series of biochemical and in vitro tumorigenic assays. On the
basis of the genomic predictions, two possible FOXM1-binding
sites, TFBS1 and TFBS2, are located near the TSS in the DLX1
promoter. TFBS1, located at +61 to +69 bp, is relatively more
conserved, whereas TFBS2, located at − 675 to − 667 bp, is less
conserved. These two binding sites, TFBS1 (ACTCCATTTT, reverse
strand AAATGGAGT) and TFBS2 (ACTCCAGCT, reverse strand
AGCTGGAGT), were identiﬁed using the Transfac database and
ARATKGAST as the FOXM1 motif for the PWM analysis. However,
this motif is different from the FOXM1 motif that was reported in a
recent study, which showed that FOXM1 is involved in modulating
the transcriptional activity of ERalpha in breast cancer.41 This
difference in the FOXM1-binding sites may be due to a cell type-
and context-speciﬁc sequences.42 For example, a recent study
used MCF7 breast cancer cells to investigate FOXM1-binding,
while we used ovarian cancer cells in this study. Moreover, the
availability of co-factors or cellular stimulators, such as estrogen, in
different cellular contexts in different tumor developing stages
may also affect the binding sites for the same transcription
factor.42 Therefore, our study found three out of 18 putative genes
could be remarkably upregulated by enforced expression of
FOXM1. Further biochemical and functional analyses revealed that
Figure 7. DLX1 is a critical downstream effector of FOXM1 that activates TGF-β1/SMAD4 signaling. (a) The western blot analysis showed
increased expression of two TGF-β signaling targets, PAI-1 and JUNB, in SKOV3 cells stably expressing DLX1 (SK-C2) in response to TGF-β1
(5 ng/ml) treatment compared with the vector control (SK-vector). (b) DLX1 induced a concentration-dependent increase in PAI-1 luciferase
activity upon TGF-β1 treatment (10 ng/ml, 3 h). (c) Depletion of DLX1 by lentiviral shRNA approach remarkably reduce the expressions of PAI-1
and JUNB in OVCA433 and SKOV3 cells upon treatment of TGF-β1 (5 ng/ml) for 5 h. (d) FOXM1 knockdown does not alter the ability of DLX1 to
upregulate PAI-1 and JUNB expression upon TGF-β1 (5 ng/ml) treatment in a SKOV3 cell model stably expressing DLX1 (SK-C2). (e) The western
blot analysis showed that SMAD4 knockdown markedly attenuated TGFβ1-induced expression of PAI-1 and JUNB, with or without stably
overexpressing DDK/DLX1 in SKOV3 cells (SK-C2 and empty vector control).
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DLX1 is a direct target of FOXM1 in mediating cell migration/
invasion of high-grade serous ovarian cancer cells. In this study,
we showed that FOXM1 could remarkably activate the DLX1
promoter, a response that was reduced by 50 and 100% when the
less conserved binding site or both binding sites were deleted,
respectively, suggesting that TFBS1 and TFBS2 are required for
FOXM1-induced activation of DLX1 transcription. Furthermore,
accumulating evidence shows that both FOXM1B and FOXM1C are
predominantly upregulated in human cancers.5,13,43–45 Indeed,
both FOXM1B and FOXM1C were able to increase the level of
DLX1, with the former exhibiting a higher capacity than the latter
in some ovarian cancer cells. This ﬁnding is consistent with our
recent ﬁnding that FOXM1B has higher oncogenic potential than
FOXM1C in human cancers.46 Numerous studies have consistently
shown that FOXM1B is essential for tumor development and
tumor metastasis.38,43–45 However, this study showed that DLX1 is
a common downstream target of both FOXM1B and FOXM1C,
while the transcriptional activity of DLX1 may be higher in some
FOXM1B-overexpressing cell lines to promote their migration and
invasion.
DLX1 is a transcription factor from the DLX homeobox family,
which shares sequence homology with the Drosophila distal-less
genes (Dll).47 To date, only a few reports have analyzed the
expression of the DLX family of transcription factors in human
cancers, and the oncogenic functions of DLX1 remain unclear. For
example, DLX4 and DLX5 have been reported to be upregulated in
ovarian carcinoma,15,18 and DLX4 enhances cancer metastasis by
activating TWIST.48 On the other hand, there are several reports
showing that DLX-1 and DLX-4 are able to interact with SMAD4
and block the autocrine TGF-β/BMP signaling cascade.17,32 Indeed,
the aberrant activation of the TGF-β signaling pathway frequently
promotes cancer progression and metastasis.49 We and others
have reported that the TGF-β-mediated cell proliferative and
metastatic activities are signiﬁcantly attenuated in high-grade
ovarian cancer.50,51 Moreover, emerging evidence has suggested
that FOXM1 interacts with TGF-β signaling in governing cancer
metastasis.52,53 The critical feature for the activation of TGF-β
signaling is the sustained accumulation of SMAD complexes in the
nuclei of cancer cells.54 On the other hand, FOXM1 is frequently
overexpressed in a variety of human cancers, including ovarian
cancer.6,55 A recent study reported that FOXM1 interacts with
SMAD3 and retains the SMAD3/SMAD4 complex in the nucleus,
thus promoting TGF-β-dependent cancer metastasis.53 Therefore,
we proposed that other factors may crosstalk with and
synergistically enhance the oncogenic capacities of these two
pathways in cancer cells. Based on the ﬁndings in this study, DLX1
is a direct target of FOXM1 and promotes cancer cell proliferation
and metastasis by interacting with SMAD4 and blocking TGF-β/
BMP signaling. In addition, DLX1 has functions similar to DLX4 and
could directly interact with nuclear SMAD4 upon TGF-β
stimulation.17,32 In contrast, SMAD4 depletion impaired DLX1-
mediated activation of TGF-β/BMP signaling as well as two key
factors, PAI-1 and JUNB, which control cancer cell migration and
invasion.34 Importantly, although FOXM1 is an oncogenic TF that
transcriptionally activates a number of oncogenes, FOXM1
knockdown failed to while DLX1 depletion could remarkably alter
these responses, suggesting that DLX1 is a dominant downstream
effector of FOXM1 in mediating ovarian cancer cell growth and
metastasis, which involves the activation of TGF-β/SMAD4
signaling.
We have demonstrated that the TGF-β-mediated expression of
PAI-1 and JUNB in high-grade ovarian cancer cells is enhanced by
DLX1. These factors are required for cancer cell metastasis
and have been shown to be transcriptionally upregulated by
TGF-β/SMAD4 signaling, as SMAD4 binding sites are present on
the PAI-1 and JUNB promoters.56,57 Intriguingly, our results
also showed that DLX1 is able to exert cell growth arrest by
blocking TGF-β/SMAD4-induced p21WAF1/Cip1 and p15Ink4B.
The co-activation of PAI-1 and JUNB in parallel with the
suppression of p21WAF1/Cip1 and p15Ink4B appears paradoxical
because these factors are downstream targets of TGF-β/SMAD4
signaling. It is known that TGF-β/SMAD4 signaling exerts its anti-
proliferative activity by transcriptional activation of the cyclin-
dependent kinase inhibitors p16INK4, p15Ink4B and p21WAF1/
Cip1 for the maintenance of normal tissue homeostasis58 and the
development of resistance to TGF-β-induced growth arrest,
particularly in advanced stage tumors.50,59 However, a recent
report supports our ﬁnding that DLX4 attenuates the anti-
proliferative action of TGF-β in cancer cells by preventing SMAD4
from forming complexes with SMAD2 and SMAD3, but not with
Sp1.17 Indeed, our ChIP assays using anti-SMAD4 antibody has
conﬁrmed that DLX1 could interfere the recruitment of SMAD4 to
the SMAD-binding elements (SBE1 and SBE2) on the p21WAF1/
Cip1 promoter in ovarian cancer cells. Therefore, given that DLX1
and DLX4 are Homeobox proteins and function similarly in their
interactions with SMAD4, we postulated that DLX1 inhibits not
only p21WAF1/Cip1 but also p15Ink4B activation in ovarian cancer
cells using the same mechanism (Supplementary Figure S7).
Furthermore, both the immunohistochemical and qRT-PCR
analyses showed that the upregulation of DLX1 was signiﬁcantly
correlated with FOXM1 expression in ovarian cancer, particularly in
high-grade tumors. High-grade ovarian tumors are well known to
be the more aggressive and metastatic ovarian cancer subtype.60
Our in vitro tumorigenic assays on several FOXM1-overexpressing
ovarian cancer cell models (for example, SKOV3 and OVCA433
cells) consistently indicated that DLX1 is a key effector of FOXM1
in promoting ovarian cancer cell proliferation and migration, as
well as tumor growth and colonization. These in vitro ﬁndings are
consistent with our clinicopathological analysis demonstrating
that concomitant expression of DLX1 and FOXM1 promotes
metastasis in high-grade ovarian cancer.
In conclusion, our data strongly support the hypothesis that
DLX1 is a novel target of FOXM1 and is highly expressed in high-
grade serous ovarian tumors. Our in vitro and in vivo functional
studies clearly showed that DLX1 possesses tumorigenic capabil-
ities, which may contribute to the aggressiveness of high-grade
serous ovarian cancers. These ﬁndings indicate that DLX1 is a
strong candidate biomarker and therapeutic target in high-grade
ovarian tumors.
MATERIALS AND METHODS
Clinical samples and cell lines
The total RNA samples from 37 normal ovaries from patients with benign
diseases and 43 ovarian cancer samples were selected for the qRT-PCR
analysis. The histological subtypes and disease stages of the tumors were
classiﬁed according to the criteria of the International Federation of
Gynaecology and Obstetrics (FIGO). The use of the clinical specimens was
approved by the local institutional ethics committee (IRB no. UW11-298).
Three immortalized human ovarian surface epithelial cell lines (HOSE 6-3,
HOSE 17-1 and HOSE 11–12), six ovarian cancer cell lines (A2780cp,
A2780s, SKOV3, OVCA429, OVCA433 and ES2) (ATCC, Rockville, MD, USA),
two cervical cancer cell lines (OV2008 and C13*) and HEK293 cells (ATCC)
were used in this study. The cell line authentication was done by in-house
STR DNA proﬁling analysis and checked for negative of mycoplasma
contamination. The FOXM1 inhibitor Thiostrepton was purchased from
Calbiochem (La Jolla, CA, USA).
Plasmids, siRNAs and cell transfection
The Myc-DDK-tagged HuDLX1 plasmid with the full length human
DLX1 cDNA (OriGene Technologies, Rockville, MD, USA) was used to
express DLX1. The pcDNA3-HA-FOXM1B and pcDNA3-HA-FOXM1C plas-
mids were used to express FOXM1B and FOXM1C, respectively.5,13 The
pTracer-CMV and pcDNA3 vectors were used as negative controls. For the
luciferase reporter assays, three DLX1 promoter fragments were subcloned
into the pGL3-basic vector (Promega Corporation, Madison, WI, USA) to
prepare pGL3-DLX1 I, pGL3-DLX II and pGL3-DLX N. pGL3-DLX I carries
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− 125 to +287 bp of the DLX1 promoter, which contains one (TFBS1) of the
two predicted FOXM1-binding sites, whereas pGL3-DLX1 II carries − 822 to
+287 bp of the DLX1 promoter, which contains both (TFBS1 and TFBS2) of
the two predicted FOXM1-binding sites. As a negative control, pGL3-DLX1
N carries +45 to − 441 bp of the DLX1 promoter, which contains neither
TFBS1 nor TFBS2. The full length p21WAF1/CIP1 promoter luciferase
construct (pWWP) (a gift from Dr Mark Feitelson, Mercer Laboratory,
Thomas Jefferson University, Philadelphia, PA, USA) and the p3TP-lux
plasmid containing a portion of the plasminogen activator inhibitor 1
(PAI-1) promoter region (Addgene, Cambridge, MA, USA) were used for
luciferase reporter assays to evaluate the transcriptional activities of
p21WAF1/CIP1 and PAI-1, respectively. The TriFECTA Dicer-substrate RNAi
kit (Integrated DNA Technologies, Inc., Singapore) includes three siRNA
duplexes targeting the human DLX1 open reading frame at three different
sites, while a scrambled siRNA duplex was used as a negative control. The
FOXM1 shRNA plasmids (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA) were used to target the human FOXM1B and FOXM1C open reading
frames, and a copGFP Control Plasmid was used as a negative control
(Santa Cruz). The CMV-GFP-T2A-Luciferase (Packaged Lentivirus) (System
Biosciences, Mountain View, CA, USA) was used for the luc-labeled cells.
The Myc-tagged SMAD4 expressing plasmid was kindly provided from Prof.
Makoto Mark Taketo (Graduate School of Medicine, Kyoto University,
Sakyo, Kyoto, Japan). Cell transfection was conducted using LipofectAMINE
2000 (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions.
RNA extraction and quantitative RT-PCR analysis
The total RNA was extracted by TRIzol as according to previously described
procedure.50 The cDNA synthesis was performed using a Reverse
transcription reagent kit (Applied Biosystems, Foster City, CA, USA). The
qRT-PCR analysis of DLX1 and p21/WAF1 expression was performed using a
Taqman Gene expression Assay with probes speciﬁc for human DLX1
(Assay ID: Hs00165626_m1), PRDM16 (Assay ID: Hs00922674_m1), FOXP2
(Assay ID: Hs00922674_m1), FOXM1 (Assay ID: Hs01073586_m1) and
p21WAF1/Cip1 (Assay ID Hs00355782_m1) (Applied Biosystems). The PCR
was performed in a 7500 Real Time PCR system (Applied Biosystems).
The relative amount of DLX1 expression was determined by the
comparative CT method using the 7500 system SDS software (Applied
Biosystems, version 1.3.1), with the 18S RNA as the internal control for
normalization.
Cell viability analysis
Cell viability was measured with the Cell Proliferation Kit II (XTT) (Roche,
Indianapolis, IN, USA), and/or BrdU Cell Proliferation Assay Kit (Biovision,
Inc., Milpitas, CA, USA), according to the manufacturer’s instructions, Three
independent experiments were performed.
Colorimetric cell migration assay
To quantify the cell migratory capacity of ovarian cancer cells, the
Transwell cell migration assay kits (Chemicon International, Inc., Temecula,
CA, USA) were used according to the manufacturer’s instructions. The
Transwell ﬁlters were visualized with a microscope (TE300, Nikon) and the
number of cells was counted. This assay was repeated at least three times.
FOXM1-binding site prediction, chromatin immunoprecipitation
(ChIP) and Luciferase reporter assays
PWMSCAN was used for the computational prediction of the FOXM1
downstream targets.61,62 The known FOXM1-binding sites are represented
in terms of the PWM, as annotated in the TRANSFAC database,63 with
a consensus motif of 'ARATKGAST' (http://cistrome.org/ ~ jian/motif_collec
tion/databases/Transfac/raw_html/M00630?view= LocusReport&protei-
n_acc = PR000007731). The transfac is a well-known database that is used
to analyze the TFBSs identiﬁed by experiments, such as EMSA or SELEX.
The human (hg18) and mouse (mm8) genomic sequences, pairwise
(human and mouse) and multiple alignment ﬁles (human, mouse, rat,
chicken, dog, chimp and pig) were obtained from the UCSC genome
database (http:--genome.ucsc.edu) and processed with an in-house
pipeline.64 The RefSeq annotated TSS was used to determine the promoter
region of the genes (2000 bp upstream to 500 bp downstream of the TSS).
The PWM of FOXM1 was used to scan the all of the human promoters with
a P-value cutoff of 10− 4, which is the probability of ﬁnding the binding site
in random sequences. The pairwise and multiple species conservations
were then checked to reduce the false positives. The highly conserved and
moderately conserved groups were deﬁned as multiple species conserva-
tion P-values of o0.001 and 0.01, respectively, and the conserved binding
sites were deﬁned as a human–mouse conservation P-valueo0.05
according to our FastPval calculation.23
The ChIP Assay Kit (Millipore, Billerica, MA, USA) was used to examine
the interaction between FOXM1 and its predicted binding sites in the DLX1
promoter, as well as the recruitment of SMAD4 to the p21WAF1/Cip1
promoter in vector control and DLX1-overexpressing cells. The immuno-
precipitated chromatin was analyzed by PCR (94 °C (8 min), 40 cycles of
94 °C (20 sec), 55 °C (20 s) FOXM1 on the DLX1 promoter) or 60 °C (SMAD4
on the p21WAF1/Cip1 promoter), and 72 °C (20 s), followed by an extension
step at 72 °C (5 min)). The PCR products were separated on a 2%
agarose gel. The ChIP primers targeted the DLX1 promoter at TFBS1 (S: 5′-
GACCTTCGCTGAGTCAAAGC-3′; AS: 5′-TCCCTTTTGGGGGTCTCTAT-3′); TFBS2
(S: 5′-GGGAGGGAAAGAGGATGTGT-3′; AS: 5′-CTCCCTGCGAACTCACTCAC
-3′); and at TFBSN (S: 5′-CGCTAGGCACAAGGCTCTTA-3′; AS: 5′-GGTCCC
TAACACCGGACAC-3′). The primers targeted the SMAD-binding elements
(SBEs) on the p21WAF1/Cip1 promoter are illustrated in Supplementary
Figure S6B.
The luciferase reporter assay was used to investigate the interaction and
transcriptional activity of FOXM1 on the DLX1 promoter. The Renilla luciferase
reporter plasmid (pRL-CMV), each pGL3-DLX1 promoter luciferase construct,
and pcDNA3-HA-FOXM1B or pcDNA3-HA-FOXM1C were co-transfected into
the HEK293 cells at different concentrations, whereas the empty vector
pcDNA3.1 was used for normalization. To analyze the effect of DLX1 on
the induction of TGF-β1/p21/WAF1 signaling, various amounts of the
Myc-DDK-tagged HuDLX1 vector with the pWWP-luciferase reporter construct
were transiently transfected into HEK293 cells. To analyze the effect of DLX1 on
PAI-1 induction, the p3TP-lux plasmid was co-transfected with various
concentrations of the Myc-DDK-tagged HuDLX1 vector into HEK293 cells.
The TGF-β1 treatment and luciferase activity analysis were the same as
reported in a previous publication.50 The dual luciferase reporter assay system
(Promega Corporation) was used to measure the ﬁreﬂy and Renilla luciferase
activity, according to a previously described protocol.65 All experiments were
repeated three separate times.
Western blot, immunopreciptation and immunohistochemical
analyses
The cell lysates were prepared from the cell pellets using Cell Lysis Buffer
(Cell Signaling Technology, Beverly, MA, USA) containing a Protease
Inhibitor Cocktail (Roche) and PMSF (phenylmethylsulphonyl ﬂuoride)
(Sigma Chemical Co., St Louis, MO, USA). The samples were separated by
SDS–polyacrylamide gel electrophoresis and electroblotted onto an
Immobilon-P Transfer Membrane (Millipore Corporation). The blots were
ﬁrst blocked with 5% skim milk, followed by incubation with primary
antibodies against FOXM1 (sc-502), p21WAF1/CIP1 (sc-397), p15Ink4B
(sc-271791), p18Ink4c(sc-865), p27Kip1(sc-528), SMAD2 (sc-7960) and SMAD4
(sc-7966) (Santa Cruz Biotechnology, Inc.), DLX1 (PA5-28899, Thermo
Scientiﬁc, Waltham, MA USA), DKK (EPR4759, OriGene Technologies,
Rockville, MD, USA), PAI-1(#612024)(BD Transduction Laboratories, San
Jose, CA, USA), JUNB(G53) (#3746) (Cell Signaling Technology), or β-actin
(A5316, Sigma). The blots were then incubated with horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse secondary antibo-
dies (Amersham Pharmacia Biotech, Cleveland, OH, USA) and visualized by
enhanced chemiluminescence (ECL) (Amersham).
The immunoprecipitation assay was performed to study the interaction of
DLX1 and SMAD4 in ovarian cancer cells, as described by Chan et al.65 Brieﬂy,
the A2780cp cells were seeded onto 100 mm culture plates, transfected with
either the Myc-DDK-tagged HuDLX1 plasmid or Myc-DKK-tagged control
plasmid and treated with TGF-β1 (1.5 ng/ml for 3 h). The cells were then
harvested in NET lysis buffer (Cell Signaling) with 1% NP40, pH 8.0, 0.1 mM
PMSF, and 1 mM Complete TM protease inhibitor cocktail (Roche). One mg of
cell lysate was incubated at 4°C with 1 μg of the mouse anti-IgG and anti-DKK
antibodies. After the incubation, 40 μl of Protein A/G Plus-Agarose beads
(Santa Cruz) were added and rotated overnight at 4 °C. After washing four
times with NET lysis buffer, sample buffer (Cell Signaling) was added and the
sample was heat denatured before electrophoresis.
Immunohistochemical staining for FOXM1 and DLX1 was performed on an
ovarian cancer tissue array (OVC1021) (Pantomics Inc., San Francisco, CA, USA)
using primary polyclonal anti-FOXM1 (Santa Cruz) and anti-DLX1 (Novus
Biologicals, LLC, Littleton, CO, USA) antibodies. The immunoreactivity for each
sample was calculated by multiplying the percentage of immunopositive cells
(10 to 100%) by the intensity of the immunostaining which was scored as 0
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(negative), 1 (faint), 2 (moderate), 3 (strong) and 4 (marked). The relative fold
change of each sample was then obtained by normalizing the immunoreactive
value of each sample with the mean value of the immunoreactivity from the
normal-benign cases. The cutoff point (fold change) for each gene was
determined according to the Receiver operating characteristic (ROC) curve. The
quantiﬁcation of the immunohistochemical staining was scored by two
independent observers.
Tumor xenograft mouse model
SKOV3-luc cells with or without DLX1 overexpression (clone 2 or C2)
(1.5 × 106 cells/100 μl) were intraperitoneally (i.p.) injected into 5-week
BALB/c nu/nu female mice with 100 μl of Matrigel Matrix (BD Biosciences,
San Jose, CA, USA). For statistical signiﬁcance, 5 mice per group were used
according to statistical calculation (36). The tumor size was monitored by
the Xenogen IVIS 100 system and Living Imaging, version 2.50.1 (Xenogen,
Alameda, CA, USA). All mice were killed on day 28 and the intraperitoneal
tumor nodules were extracted and weighed. All of the animal experiments
were approved by the University of Hong Kong Committee on the Use of
Live Animals in Teaching and Research (CULATR No.2560-11).
Statistical analysis
The clinical parameters were analyzed by SPSS 13.0 software (SPSS,
Chicago, IL, USA). Fisher’s exact test (for parametric data) and the Mann-
Whitney test (for non-parametric data) were used to compare the values
between subgroups. The Student’s t-test was used to analyze the cell
viability and migration data. A P-value of o0.05 was considered
statistically signiﬁcant.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We thank Dr Shigeru Chiba (Division of Hematology, Institute of Clinical Medicine,
University of Tsukuba, Japan) for providing pTracer-CMV-DLX1-Flag plasmid,
Professor Makoto Mark Taketo (Graduate School of Medicine, Kyoto University,
Sakyo, Kyoto, Japan) for providing Myc-tagged SMAD4 expressing plasmid, and Prof.
George Tsao (Department of Anatomy, The University of Hong Kong) for providing
HOSE 6-3, HOSE 17-1 and HOSE 11-12. This study was supported by Wong Check She
Charitable Foundation.
AUTHOR CONTRIBUTIONS
DWC and WWYH designed the research. DWC, WWYH, JW, LMNH and MMHY
performed the experiments. DWC, THYL, KKLC, YQ, JW and K-MY contributed
new reagents-analytic tools. DWC, WWYH, JW, YQ, DX, K-MY, BKT and HYSN
analyzed and interpreted the data. DWC wrote the manuscript. All authors were
involved in editing the manuscript and had ﬁnal approval of the submitted and
published versions.
REFERENCES
1 Myatt SS, Lam EW. Targeting FOXM1. Nat Rev Cancer 2008; 8: 242.
2 Costa RH, Kalinichenko VV, Holterman AX, Wang X. Transcription factors in
liver development, differentiation, and regeneration. Hepatology 2003; 38:
1331–1347.
3 Kim IM, Ramakrishna S, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV.
The forkhead box m1 transcription factor is essential for embryonic development
of pulmonary vasculature. J Biol Chem 2005; 280: 22278–22286.
4 Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer.
Biochim Biophys Acta 2007; 1775: 92–102.
5 Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW, Cheung AN et al. Over-expression of
FOXM1 transcription factor is associated with cervical cancer progression and
pathogenesis. J Pathol 2008; 215: 245–252.
6 Wen N, Wang Y, Wen L, Zhao SH, Ai ZH, Wang Y et al. Overexpression of FOXM1
predicts poor prognosis and promotes cancer cell proliferation, migration and
invasion in epithelial ovarian cancer. J Transl Med 2014; 12: 134.
7 Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ et al. Overexpression of FOXM1
is associated with poor prognosis and clinicopathologic stage of pancreatic ductal
adenocarcinoma. Pancreas 2012; 41: 629–635.
8 Zeng J, Wang L, Li Q, Li W, Bjorkholm M, Jia J et al. FoxM1 is up-regulated in
gastric cancer and its inhibition leads to cellular senescence, partially dependent
on p27 kip1. J Pathol 2009; 218: 419–427.
9 Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian
carcinoma. Nature 2011; 474: 609–615.
10 Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A et al. Over-expression of
FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell pheno-
type in pancreatic cancer cells. J Cell Biochem 2011; 112: 2296–2306.
11 Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD et al. A novel FoxM1-caveolin
signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer
Res 2012; 72: 655–665.
12 Raychaudhuri P, Park HJ. FoxM1: a master regulator of tumor metastasis.
Cancer Res 2011; 71: 4329–4333.
13 Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM et al. Aberrant activation of
ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian
cancer cells. PloS One 2011; 6: e23790.
14 Merlo GR, Zerega B, Paleari L, Trombino S, Mantero S, Levi G. Multiple functions of
Dlx genes. Int J Dev Biol 2000; 44: 619–626.
15 Morini M, Astigiano S, Gitton Y, Emionite L, Mirisola V, Levi G et al. Mutually
exclusive expression of DLX2 and DLX5/6 is associated with the metastatic
potential of the human breast cancer cell line MDA-MB-231. BMC Cancer 2010; 10:
649.
16 Hara F, Samuel S, Liu J, Rosen D, Langley RR, Naora H. A homeobox gene related
to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression
of vascular endothelial growth factor and ﬁbroblast growth factor-2. Am J Pathol
2007; 170: 1594–1606.
17 Trinh BQ, Barengo N, Naora H. Homeodomain protein DLX4 counteracts key
transcriptional control mechanisms of the TGF-beta cytostatic program and
blocks the antiproliferative effect of TGF-beta. Oncogene 2011; 30: 2718–2729.
18 Tan Y, Cheung M, Pei J, Menges CW, Godwin AK, Testa JR. Upregulation of DLX5
promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.
Cancer Res 2010; 70: 9197–9206.
19 Starkova J, Gadgil S, Qiu YH, Zhang N, Hermanova I, Kornblau SM et al.
Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling.
Haematologica 2011; 96: 820–828.
20 Maira M, Long JE, Lee AY, Rubenstein JL, Stifani S. Role for TGF-beta superfamily
signaling in telencephalic GABAergic neuron development. J Neurodev Disord
2010; 2: 48–60.
21 Pleasure SJ, Anderson S, Hevner R, Bagri A, Marin O, Lowenstein DH et al.
Cell migration from the ganglionic eminences is required for the development of
hippocampal GABAergic interneurons. Neuron 2000; 28: 727–740.
22 Cantile M, Kisslinger A, Cindolo L, Schiavo G, D'Anto V, Franco R et al. cAMP
induced modiﬁcations of HOX D gene expression in prostate cells allow the
identiﬁcation of a chromosomal area involved in vivo with neuroendocrine
differentiation of human advanced prostate cancers. J Cell Physiol 2005; 205:
202–210.
23 Li MJ, Sham PC, Wang J. FastPval: a fast and memory efﬁcient program to
calculate very low P-values from empirical distribution. Bioinformatics 2010; 26:
2897–2899.
24 Lam AK, Ngan AW, Leung MH, Kwok DC, Liu VW, Chan DW et al. FOXM1b, which is
present at elevated levels in cancer cells, has a greater transforming potential
than FOXM1c. Front Oncol 2013; 3: 11.
25 Potter GB, Petryniak MA, Shevchenko E, McKinsey GL, Ekker M, Rubenstein JL.
Generation of Cre-transgenic mice using Dlx1/Dlx2 enhancers and their char-
acterization in GABAergic interneurons. Mol Cell Neurosci 2009; 40: 167–186.
26 Cobos I, Calcagnotto ME, Vilaythong AJ, Thwin MT, Noebels JL, Baraban SC et al.
Mice lacking Dlx1 show subtype-speciﬁc loss of interneurons, reduced inhibition
and epilepsy. Nat Neurosci 2005; 8: 1059–1068.
27 Cobos I, Borello U, Rubenstein JL. Dlx transcription factors promote migration
through repression of axon and dendrite growth. Neuron 2007; 54: 873–888.
28 Le TN, Du G, Fonseca M, Zhou QP, Wigle JT, Eisenstat DD. Dlx homeobox genes
promote cortical interneuron migration from the basal forebrain by direct
repression of the semaphorin receptor neuropilin-2. J Biol Chem 2007; 282:
19071–19081.
29 Lin SW, Lee MT, Ke FC, Lee PP, Huang CJ, Ip MM et al. TGFbeta1 stimulates the
secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in
human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin
Exp Metastasis 2000; 18: 493–499.
30 Lin SW, Ke FC, Hsiao PW, Lee PP, Lee MT, Hwang JJ. Critical involvement of ILK in
TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is
associated with urokinase plasminogen activator system. Exp Cell Res 2007; 313:
602–613.
31 Teng Y, Zhao L, Zhang Y, Chen W, Li X. Id-1, a protein repressed by miR-29b,
facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human
ovarian cancer cells. Cell Physiol Biochem 2014; 33: 717–730.
DLX1 acts as a crucial target of FOXM1
DW Chan et al
12
Oncogene (2016) 1 – 13
32 Chiba S, Takeshita K, Imai Y, Kumano K, Kurokawa M, Masuda S et al.
Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway
from activin A in hematopoietic cells. Proc Natl Acad Sci USA 2003; 100:
15577–15582.
33 Yang N, Zhao B, Rasul A, Qin H, Li J, Li X. PIAS1-modulated Smad2/4 complex
activation is involved in zinc-induced cancer cell apoptosis. Cell Death Dis 2013; 4:
e811.
34 Sundqvist A, Zieba A, Vasilaki E, Herrera Hidalgo C, Soderberg O, Koinuma D
et al. Speciﬁc interactions between Smad proteins and AP-1 components
determine TGFbeta-induced breast cancer cell invasion. Oncogene 2013; 32:
3606–3615.
35 Shiou SR, Datta PK, Dhawan P, Law BK, Yingling JM, Dixon DA et al. Smad4-
dependent regulation of urokinase plasminogen activator secretion and RNA
stability associated with invasiveness by autocrine and paracrine transforming
growth factor-beta. J Biol Chem 2006; 281: 33971–33981.
36 Wierstra I. The transcription factor FOXM1 (Forkhead box M1): proliferation-
speciﬁc expression, transcription factor function, target genes, mouse models,
and normal biological roles. Adv Cancer Res 2013; 118: 97–398.
37 Koo CY, Muir KW, Lam EW. FOXM1: From cancer initiation to progression and
treatment. Biochim Biophys Acta 2012; 1819: 28–37.
38 Dai B, Kang SH, Gong W, Liu M, Aldape KD, Sawaya R et al. Aberrant FoxM1B
expression increases matrix metalloproteinase-2 transcription and enhances the
invasion of glioma cells. Oncogene 2007; 26: 6212–6219.
39 Gusarova GA, Wang IC, Major ML, Kalinichenko VV, Ackerson T, Petrovic V et al.
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular
carcinoma treatment. J Clin Invest 2007; 117: 99–111.
40 Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box M1
transcription factor leads to the inhibition of invasion and angiogenesis of
pancreatic cancer cells. Cancer Res 2007; 67: 8293–8300.
41 Sanders DA, Ross-Innes CS, Beraldi D, Carroll JS, Balasubramanian S. Genome-wide
mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in
breast cancer cells. Genome Biol 2013; 14: R6.
42 Eeckhoute J, Metivier R, Salbert G. Deﬁning speciﬁcity of transcription factor
regulatory activities. J Cell Sci 2009; 122: 4027–4034.
43 Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM et al. Foxm1b
transcription factor is essential for development of hepatocellular carcinomas and
is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004; 18:
830–850.
44 Park HJ, Gusarova G, Wang Z, Carr JR, Li J, Kim KH et al. Deregulation of FoxM1b
leads to tumour metastasis. EMBO Mol Med 2011; 3: 21–34.
45 Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K et al. FoxM1B transcriptionally
regulates vascular endothelial growth factor expression and promotes the
angiogenesis and growth of glioma cells. Cancer Res 2008; 68: 8733–8742.
46 Lam AY, Ngan AW, Leung MH, Kwok DC, Liu VW, Chan DW et al. FOXM1b, which is
present at elevated levels in cancer cells, has a greater transforming potential
than FOXM1c. Front Mol Cell Oncol 2013; 3: 1–3.
47 Lezot F, Thomas B, Greene SR, Hotton D, Yuan ZA, Castaneda B et al. Physiological
implications of DLX homeoproteins in enamel formation. J Cell Physiol 2008; 216:
688–697.
48 Zhang L, Yang M, Gan L, He T, Xiao X, Stewart MD et al. DLX4 upregulates TWIST
and enhances tumor migration, invasion and metastasis. Int J Biol Sci 2012; 8:
1178–1187.
49 Papageorgis P. TGFbeta signaling in tumor initiation, epithelial-to-mesenchymal
transition, and metastasis. J Oncol 2015; 2015: 587193.
50 Chan DW, Liu VW, To RM, Chiu PM, Lee WY, Yao KM et al. Overexpression of
FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1
expression in ovarian cancer. Br J Cancer 2009; 101: 1433–1443.
51 Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF et al. EZH2 supports ovarian
carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a
predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010; 31:
1576–1583.
52 Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y et al. miR-134 inhibits epithelial to
mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells.
FEBS Lett 2012; 586: 3761–3765.
53 Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M et al. Sustained activation of SMAD3/
SMAD4 by FOXM1 promotes TGF-beta-dependent cancer metastasis. J Clin Invest
2014; 124: 564–579.
54 Moustakas A, Heldin CH. The regulation of TGFbeta signal transduction.
Development 2009; 136: 3699–3714.
55 Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in
human cancer, implication in tumorigenesis, oncogenic functions, tumor-
suppressive properties, and target of anticancer therapy. Adv Cancer Res 2013;
119: 191–419.
56 Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of
Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter
of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17:
3091–3100.
57 Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identiﬁcation and functional
characterization of a Smad binding element (SBE) in the JunB promoter that acts
as a transforming growth factor-beta, activin, and bone morphogenetic protein-
inducible enhancer. J Biol Chem 1998; 273: 21145–21152.
58 He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J.
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the
TGFbeta pathway. Cell 2006; 125: 929–941.
59 Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer
Metastasis Rev 2006; 25: 435–457.
60 Chan DW, Hui WW, Cai PC, Liu MX, Yung MM, Mak CS et al. Targeting GRB7/ERK/
FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.
PloS One 2012; 7: e52578.
61 Levy S, Hannenhalli S. Identiﬁcation of transcription factor binding sites in the
human genome sequence. Mammalian Genome 2002; 13: 510–514.
62 Wang JW, Zhang SL, Schultz RM, Tseng H. Search for basonuclin target genes.
Biochem Biophys Res Commun 2006; 348: 1261–1271.
63 Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A et al.
TRANSFAC and its module TRANSCompel: transcriptional gene regulation in
eukaryotes. Nucleic Acids Res 2006; 34: D108–D110.
64 Qin J, Li MLJ, Wang PW, Zhang MQ, Wang JW. ChIP-Array: combinatory analysis of
ChIP-seq/chip and microarray gene expression data to discover direct/indirect
targets of a transcription factor. Nucleic Acids Res 2011; 39: W430–W436.
65 Chan DW, Liu VW, Leung LY, Yao KM, Chan KK, Cheung AN et al. Zic2 synergis-
tically enhances Hedgehog signalling through nuclear retention of Gli1 in cervical
cancer cells. J Pathol 2011; 225: 525–534.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) 2016
Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)
DLX1 acts as a crucial target of FOXM1
DW Chan et al
13
Oncogene (2016) 1 – 13
